Performance of the new Platelia Candida Plus assays for the diagnosis of invasive Candida infection in patients undergoing myeloablative therapy

Medical Mycology

Volumn 49, Issue 8, 2011, Pages 848-855

  Verduyn Lunel, Frans M ^a,b   Peter Donnelly, J ^b   Van Der Lee, Henrich A L ^a,b   Blijlevens, Nicole M A ^b   Verweij, Paul E ^a,b  

^a Department of Medical Microbiology ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody; Antigen; Candida; Haematology; Kinetics; Neutropenia

Indexed keywords

BETA 1,3 GLUCAN; CANDIDA ANTIGEN; FUNGUS ANTIBODY;

ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; FUNGAL DETECTION; HUMAN; IMMUNOASSAY; MICROBIOLOGICAL EXAMINATION; MYELOABLATIVE CONDITIONING; NEUTROPENIA; PLASMA; PLATELIA CANDIDA PLUS ASSAY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SERUM; SURVIVAL RATE;

ANTIBODIES, FUNGAL; ANTIGENS, FUNGAL; CANDIDA; CANDIDIASIS, INVASIVE; CLINICAL LABORATORY TECHNIQUES; FUNGEMIA; HUMANS; MANNANS; MYELOABLATIVE AGONISTS; NEUTROPENIA; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

CANDIDA;

EID: 80054688814     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.582889     Document Type: Article

References (11)

1. Verduyn Lunel FM, Donnelly JP, van der Lee HAL, Blijlevens NMA, Verweij PE. Circulating Candida-specif c antimannan antibodies precede invasive candidiasis in patients treated with myeloablative chemotherapy. Clin Microbiol Infect 2009; 15: 380-386.
2. Verduyn Lunel FM, Mennink-Kersten MA, Ruegebrink D, et al. Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn Microbiol Infect Dis 2009; 64: 408-415.
3. Sendid B, Poirot JL, Tabouret M, et al. Combined detection of man-nanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002; 51: 433-442 (Pubitemid 34450601)
4. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-1336. (Pubitemid 46729195)
5. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645. (Pubitemid 41233011)
6. Garey KW, Rege M, Pai MP, et al. Time to initiation of f uconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31. (Pubitemid 43939072)
7. R Foundation for Statistical Computing. R: A language and environment for statistical computing. Version 2.10.1. Vienna, Austria: R Foundation for Statistical Computing; 2009.
8. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-357. (Pubitemid 38692699)
9. Mennink-Kersten MA, Ruegebrink D, Klont RR, et al. Improved detection of circulating Aspergillus antigen by use of a modif ed pre-treatment procedure. J Clin Microbiol 2008; 46: 1391-1397. (Pubitemid 351563585)
10. de Repentigny L, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodef ciency virus infection. Clin Microbiol Rev 2004; 17: 729-759. (Pubitemid 39372514)
11. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the ssInfectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.